Trial Profile
A phase I, multi-dose study of SGN-40 (anti-huCD40 mAb) in patients with non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Dacetuzumab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Seagen
- 09 Oct 2008 Actual patient number is 50; study end date changed from July to March 2007, as reported by ClinicalTrials.gov.
- 09 Oct 2008 Genentech reported as a trial Sponsor by ClinicalTrials.gov.
- 06 Jun 2008 Final results were reported during an oral presentation at the International Conference on Malignant Lymphoma (ICML).